Accelrys Cuts Loss 84 Percent on Slight Quarterly Revenue Gain

May 16, 2007

NEW YORK (GenomeWeb News) - Accelrys yesterday reported a 2 percent increase in fiscal fourth-quarter revenues as R&D spending fell 22 percent and the company cut its quarterly loss by 84 percent.

Total receipts for the three months ended March 31, 2007, increased to $19.9 million from $19.4 million year over year.

Accelrys said growth in its SciTegic Pipeline Pilot product line was offset by reduced sales of legacy products that were “deemphasized" due to product line restructuring.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Microsoft, But the Brain, Too

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

Been Reclassified

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

This Week in Cell

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

Pursuit of a Cancer Vaccine

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu